Akero治疗技术公司开发了一种新型的代谢性疾病治疗方法,发现股票增长强劲,分析师买入评级。 Akero Therapeutics, developing a novel metabolic disease treatment, sees strong stock growth and analyst buy ratings.

Akero治疗学(NASDAQ:AKRO)是一家开发新陈代谢疾病治疗的公司,是需要购买的最高保健储备之一,迄今的绩效为43.24%。 Akero Therapeutics (NASDAQ:AKRO), a company developing treatments for metabolic diseases, is among the top healthcare stocks to buy, with a year-to-date performance of 43.24%. 该公司的产品(efruxifermin)处于第3阶段试验,没有经过批准的疗法。 The company's product, efruxifermin, is in phase 3 trials for a condition with no approved therapies. 来自美国银行和Clear Street的分析师保持了买入评级,价格目标分别为63.00美元和49美元,并引述了该药物的潜力。 Analysts from Bank of America and Clear Street have maintained a Buy rating, with price targets of $63.00 and $49, respectively, citing the drug's potential.